Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

(1) CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE; AND (2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES 2026-04-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026 2026-04-08
VOLUNTARY ANNOUNCEMENT – A PHASE III CLINICAL STUDY OF KN026 FOR NEOADJUVANT TREATMENT OF HER2+ BC MET PRIMARY ENDPOINT 2026-03-31
Announcements and Notices - ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 2026-03-26
VOLUNTARY ANNOUNCEMENT – FIRST PATIENT DOSED IN PHASE III CLINICAL STUDY OF KN026 FOR ADJUVANT TREATMENT OF HER2+ BC 2026-03-24
VOLUNTARY ANNOUNCEMENT – FIRST PATIENT DOSED IN A PHASE III CLINICAL STUDY OF JSKN016 FOR THE TREATMENT OF TNBC 2026-03-20
VOLUNTARY ANNOUNCEMENT – APPOINTMENT OF CHIEF FINANCIAL OFFICER 2026-03-18
VOLUNTARY ANNOUNCEMENT – FIRST PATIENT DOSED IN A PHASE I CLINICAL STUDY OF JSKN027 2026-03-16
VOLUNTARY ANNOUNCEMENT – IND APPLICATION FOR JSKN021 WAS OFFICIALLY ACCEPTED BY THE CDE 2026-03-13
DATE OF BOARD MEETING 2026-03-11